Larvol Delta - Tris-Pharma-Reports-Positive-Topline-Data-from-Clinical-Study-of-Investigational-Pain-Therapy-Cebranopadol-Showing-Signicantly-Less-Potential-for-Abuse-Versus-Tramadol-and-Oxycodone

cebranopadol (TRN-228) - Tris Pharma

https://www.prnewswire.com/news-releases/tris-pharma-reports-positive-topline-data-from-clinical-study-of-investigational-pain-therapy-cebranopadol-showing-significantly-less-potential-for-abuse-versus-tramadol-and-oxycodone-301701284.html

Dec 13, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next